Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan Dubow

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Sleep|May 29, 2023
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON TrialYves Dauvilliers, Thomas Roth, Richard Bogan, et al.
CNS Drugs|April 5, 2022
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialThomas Roth, Yves Dauvilliers, Michael J Thorpy, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's DiseaseJeffrey F Waring, Qi Tang, Weining Z Robieson, et al.
Clinical and Translational Gastroenterology|April 1, 2016
Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's DiseaseMichael Epstein, David A Johnson, Robert Hawes, et al.
Eclinicalmedicine|October 29, 2024
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trialNicola L Brice, Mark Carlton, David H Margolin, et al.
Sleep|August 6, 2021
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsyClete A Kushida, Colin M Shapiro, Thomas Roth, et al.
Headache|September 1, 2006
The relation of brain ouabain-like compounds and idiopathic intracranial hypertensionMark Borsody, Irene Semenov, Kathleen Carroll, et al.
Neurology and Therapy|June 15, 2025
Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson's DiseaseGil L'Italien, Basia Rogula, Lauren Powell, et al.
Parkinsonism & Related Disorders|October 17, 2025
Development of composite scales for assessing disease progression and treatment effects among patients with Parkinson's disease in a clinical trial settingGil L'Italien, Basia Rogula, Lauren C Powell, et al.
Stroke (Hoboken, N.J.)|May 6, 2026
RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known WellSupurna Ghosh, Jordan Dubow, Christopher G Favilla, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Sleep|May 29, 2023
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON TrialYves Dauvilliers, Thomas Roth, Richard Bogan, et al.
CNS Drugs|April 5, 2022
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialThomas Roth, Yves Dauvilliers, Michael J Thorpy, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's DiseaseJeffrey F Waring, Qi Tang, Weining Z Robieson, et al.
Clinical and Translational Gastroenterology|April 1, 2016
Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's DiseaseMichael Epstein, David A Johnson, Robert Hawes, et al.
Eclinicalmedicine|October 29, 2024
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trialNicola L Brice, Mark Carlton, David H Margolin, et al.
Sleep|August 6, 2021
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsyClete A Kushida, Colin M Shapiro, Thomas Roth, et al.
Headache|September 1, 2006
The relation of brain ouabain-like compounds and idiopathic intracranial hypertensionMark Borsody, Irene Semenov, Kathleen Carroll, et al.
Neurology and Therapy|June 15, 2025
Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson's DiseaseGil L'Italien, Basia Rogula, Lauren Powell, et al.
Parkinsonism & Related Disorders|October 17, 2025
Development of composite scales for assessing disease progression and treatment effects among patients with Parkinson's disease in a clinical trial settingGil L'Italien, Basia Rogula, Lauren C Powell, et al.
Stroke (Hoboken, N.J.)|May 6, 2026
RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known WellSupurna Ghosh, Jordan Dubow, Christopher G Favilla, et al.
Pageof 3